共 50 条
- [41] Results from a Phase 1 Dose Escalation Study of HMPL-689, a Selective Oral Phosphoinositide 3Kinase-Delta Inhibitor, in Chinese Patients with Relapsed/Refractory (R/R) LymphomasBLOOD, 2020, 136Cao, JunningLi, ZhimingZhou, JianfengJi, DongmeiShen, WeinaSun, PengWang, YuLi, DengjuHong, ZhenyaWang, GaoxiangDuan, XianlinYu, ChenCai, YuSu, Weiguo
- [42] A Phase 2 Randomized Clinical Trial to Evaluate the Safety and Efficacy of Pegylated Interferon Lambda Monotherapy in Patients with Chronic Hepatitis Delta Virus Infection. Interim Results From the LIMT HDV StudyHEPATOLOGY, 2017, 66 : 496A - 496AHamid, Saeed S.Etzion, OhadLurie, YoavBader, NimrahYardeni, DavidChanna, Saleh M.Mawani, MinazParkash, OmMartins, Eduardo B.Gane, Edward J.
- [44] EFFICACY AND SAFETY OF BLV MONOTHERAPY FOR CHRONIC HEPATITIS DELTA: POST TREATMENT RESULTS THROUGH 48 WEEKS AFTER THE END OF TREATMENT FROM AN INTERIM ANALYSIS OF A RANDOMIZED PHASE 3 STUDY MYR301HEPATOLOGY, 2024, 80 : S107 - S108Chee, GraceAleman, SooBrunetto, MauriziaBlank, AntjeAndreone, PietroBogomolov, PavelChulanov, VladimirMamonova, NinaGeyvandova, NataliaViacheslav, MorozovSagalova, OlgaStepanova, TatyanaManuilov, DmitryArterburn, SarahLau, AudreyOsinusi, AnuChristian-Cox, FlorenceDuff, FrankZur Wiesch, Julian SchulzeCornberg, MarkusZeuzem, StefanWedemeyer, HeinerLampertico, Pietro
- [45] Initial results from a phase I study of Nous-209, an off-the-shelf viral vectored immunotherapy encoding 209 shared frame shift peptide neoantigens, with pembrolizumab, for the treatment of tumors with a deficiency in mismatch repair/microsatellite instabilityANNALS OF ONCOLOGY, 2021, 32 : S850 - S850Overman, M. J.Leoni, G.D'Alise, A. M.Cotugno, G.Langone, F.Capone, S.Del Sorbo, M.Fakih, M.Le, D. T.Shields, A. F.Pedersen, K. S.Shah, M. A.Mukherjee, S.Delaite, P.Faivre, T.Scarselli, E.
- [46] EFFICACY AND SAFETY OF BULEVIRTIDE IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2a IN PATIENTS WITH CHRONIC HEPATITIS DELTA: PRIMARY ENDPOINT RESULTS FROM A PHASE 2b OPEN-LABEL, RANDOMIZED, MULTICENTER STUDY MYR204HEPATOLOGY, 2024, 79 (02) : E43 - E44Asselah, TarikLampertico, PietroWedemeyer, HeinerStreinu-Cercel, AdrianPantea, VictorLazar, StefanPlacinta, GheorgheGherlan, George SebastianBogomolov, PavelStepanova, TatianaMorozov, ViacheslavChulanov, VladimirSyutkin, Vladimir E.Sagalova, OlgaGorodin, VladmirManuilov, DmitryMercier, Renee-ClaudeYe, LeiFlaherty, John F.Osinusi, Anu O.Lau, Audrey H.Da, Ben L.Bourliere, MarcRatziu, VladPol, StanislasHilleret, Marie-NoelleZoulim, Fabien
- [47] Efficacy and safety of bulevirtide in combination with pegylated interferon alfa-2a in patients with chronic hepatitis delta: Primary endpoint results from the phase 2b, open-label, randomized, multicenter study MYR204JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 : 104 - 105Asselah, TarikLampertico, PietroWedemeyer, HeinerStreinu-Cercel, AdrianPantea, VictorLazar, StefanPlacinta, GheorgheGherlan, George SebastianBogomolov, PavelStepanova, TatyanaMorozov, ViacheslavChulanov, VladimirSyutkin, VladimirSagalova, OlgaGorodin, VladimirManuilov, DmitryMercier, Renee-ClaudeYe, LeiFlaherty, John F.Freismuth, AurelieOsinusi, AnuLau, AudreyDa, BenBourliere, MarcRatziu, VladPol, StanislasHilleret, Marie-NoelleZoulim, Fabien
- [48] Single- and multiple-dose safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of ASP0367, or bocidelpar sulfate, a novel modulator of peroxisome proliferator-activated receptor delta in healthy adults: Results from a phase 1 studyMUSCLE & NERVE, 2022, 65 (01) : 110 - 120Ito, MototsuguTauscher-Wisniewski, SitraSmulders, Ronald A.Wojtkowski, TomaszYamada, AkihiroKoibuchi, AkiraUz, TolgaMarek, Gerard J.Goldwater, Ronald D.
- [49] Initial Results from a Phase 1 Single Ascending Dose Clinical Trial of STAR-0215, an Investigational Long-Acting Monoclonal Antibody Plasma Kallikrein Inhibitor for Hereditary Angioedema (HAE), in Healthy Subjects Followed for at Least 3 MonthsJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB136 - AB136Morabito, ChristopherStevens, ChrisChung, Jou-KuDagher, RafifBista, PradeepBernard, KristineGustafson, PamelaGunsior, MicheleNichols, Andy
- [50] Initial results from a Phase 1 single ascending dose clinical trial of STAR-0215, an investigational long-acting monoclonal antibody plasma kallikrein inhibitor for hereditary angioedema (HAE), in healthy subjects followed for at least 3 monthsALLERGY, 2023, 78 : 30 - 30Morabito, C.Stevens, C.Chung, J. K.Gunsior, M.Bernard, K.Gustafson, P.Bista, P.Magill, M.Nichols, A.Lumry, W.